Literature DB >> 2121913

Can iodine-131 whole-body scan be replaced by thyroglobulin measurement in the post-surgical follow-up of differentiated thyroid carcinoma?

G Ronga1, A Fiorentino, E Paserio, A Signore, V Todino, M A Tummarello, M Filesi, I Baschieri.   

Abstract

This study compared serum thyroglobulin measurement and whole-body scans in the post-surgical follow-up of patients with differentiated thyroid carcinoma. Thyroglobulin levels were measured in 61 patients receiving L-thyroxine therapy after thyroidectomy, and again after suspension of therapy, before performing a whole-body scan with iodine-131. The sensitivity, specificity, and accuracy of thyroglobulin levels, measured during L-thyroxine therapy, for diagnosis of tumor residue or metastases were then calculated and compared with results obtained by diagnostic whole-body scanning. Our data show that neither thyroglobulin levels nor whole-body scans alone can discriminate between patients with or without metastases. Sensitivity reached 95.7%, specificity 100%, and accuracy 96.7% if results of both procedures were also taken into consideration. We conclude that in the management and follow-up of patients with differentiated thyroid carcinoma both parameters need to be evaluated.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2121913

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  11 in total

1.  Radiation dose rates from patients receiving iodine-131 therapy for carcinoma of the thyroid.

Authors:  S F Barrington; A G Kettle; M J O'Doherty; C P Wells; E J Somer; A J Coakley
Journal:  Eur J Nucl Med       Date:  1996-02

2.  False positive 131I total body scan due to an ectasia of the common carotidis.

Authors:  D Giuffrida; M R Garofalo; G Cacciaguerra; V Freni; A Ippolito; C Regalbuto; M G Santonocito; A Belfiore
Journal:  J Endocrinol Invest       Date:  1993-03       Impact factor: 4.256

3.  Value of 111In-DOTA-lanreotide and 111In-DOTA-DPhe1-Tyr3-octreotide in differentiated thyroid cancer: results of in vitro binding studies and in vivo comparison with 18F-FDG PET.

Authors:  Margarida Rodrigues; Tatjana Traub-Weidinger; Maria Leimer; Shuren Li; Fritz Andreae; Peter Angelberger; Robert Dudczak; Irene Virgolini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-05-21       Impact factor: 9.236

4.  Diagnostic 131I whole-body scintigraphy 1 year after thyroablative therapy in patients with differentiated thyroid cancer: correlation of results to the individual risk profile and long-term follow-up.

Authors:  Frank Berger; Ulla Friedrich; Peter Knesewitsch; Klaus Hahn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-11-18       Impact factor: 9.236

5.  Recurrent thyroid cancer. Role of surgery versus radioactive iodine (I131)

Authors:  M Coburn; D Teates; H J Wanebo
Journal:  Ann Surg       Date:  1994-06       Impact factor: 12.969

6.  Practice trends in patients with persistent detectable thyroglobulin and negative diagnostic radioiodine whole body scans: a survey of American Thyroid Association members.

Authors:  Robert C Smallridge; Nancy Diehl; Victor Bernet
Journal:  Thyroid       Date:  2014-09-05       Impact factor: 6.568

7.  Role of technetium(99m) scan in detecting residual thyroid disease.

Authors:  Sanjeev Mohanty
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2006-07

8.  99mTc-EDDA/HYNIC-TOC and (18)F-FDG in thyroid cancer patients with negative (131)I whole-body scans.

Authors:  Michael Gabriel; Franz Froehlich; Clemens Decristoforo; Christian Ensinger; Eveline Donnemiller; Elisabeth von Guggenberg; Dirk Heute; Roy Moncayo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-11-19       Impact factor: 9.236

9.  Utility of (99m)Tc-Hynic-TOC in 131I Whole-Body Scan Negative Thyroid Cancer Patients with Elevated Serum Thyroglobulin Levels.

Authors:  Ajit S Shinto; K K Kamaleshwaran; Madhav Mallia; Aruna Korde; Grace Samuel; Sharmila Banerjee; Pavanasam Velayutham; Suresh Damodharan; Madhu Sairam
Journal:  World J Nucl Med       Date:  2015 May-Aug

10.  Uptake of (18) FDG by a Hepatic Adenoma on Positron Emission Tomography.

Authors:  J A Stephenson; T Kapasi; O Al-Taan; A R Dennison
Journal:  Case Reports Hepatol       Date:  2011-12-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.